Here, we report that ARE/SUZ12-regulated HSV-TK/GCV therapy is effective and specific for BP-CML cells in vitro, and this may offer an attractive therapeutic approach for treating BP-CML in the future. Here, SUZ12 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.